Table 1. Effect of IAE and reference compounds on proliferation of HT-29 and T84 colon carcinoma cells, PC-3 prostate cancer, MCF7 breast cancer and normal CCD 841 CoN colon cells.
| Cell lines | IC50 and Efficacy | IAE | Irinotecan | 5-FU | Oxaliplatin |
|---|---|---|---|---|---|
| HT-29 (Colon cancer) | IC50 (μg/ml) | 6.3 ± 0.9 | 1.5 ± 0.5 | 0.7 ± 0.1 | 0.8 ± 0.2 |
| Efficacy (%) | 71.8 ± 2.1 | 78.7 ± 5.8 | 71.4 ± 5.0 | 67.7 ± 3.9 | |
| T-84 (Colon cancer) | IC50 (μg/ml) | 9.0 ± 0.5 | 0.7 ± 0.2 | 0.9 ± 3.0 | 0.4 ± 0.1 |
| Efficacy (%) | 79.9 ± 1.6 | 81.0 ± 4.8 | 86.2 ± 31.8 | 88.4 ± 3.9 | |
| PC3 (Prostate cancer) | IC50 (μg/ml) | 43.8 ± 3.6 | 0.5 ± 0.1 | 0.6 ± 0.0 | 0.3 ± 0.0 |
| Efficacy (%) | 44.2 ± 1.6 | 76.0 ± 2.3 | 79.4 ± 1.5 | 86.5 ± 1.6 | |
| MCF-7 (Breast cancer) | IC50 (μg/ml) | 11.1 ± 1.1 | 0.5 ± 0.1 | 0.1 ± 0.0 | 0.2 ± 0.0 |
| Efficacy (%) | 75.7 ± 2.7 | 80.2 ± 3.8 | 78.4 ± 1.6 | 84.7 ± 2.1 | |
| CCD 841 CoN (Colon normal) | IC50 (μg/ml) | 0.5 ± 2.3 | 5.0 ± 19.2 | 0.1 ± 0.0 | 0.3 ± 0.3 |
| Efficacy (%) | 59.6 ± 6.7 | 58.0 ± 24.7 | 41.0 ± 1.4 | 48.9 ± 6.4 |
Efficiency is the maximal observed induction of cell death after treatment relative to nontreated cells (set to 0%).